N. Al-Sakaff

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

David Cameron, Martine Piccart, Richard D. Gelber et al. · The Lancet · 2017 · 1K citations · Full text

Medicine, Immunology, Oncology +17

Role of Troponins I and T and <i>N</i>-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy

Dimitrios Zardavas, Thomas Suter, Dirk J. van Veldhuisen et al. · Journal of Clinical Oncology · 2017 · 165 citations

Medicine, Cardiology, Oncology +17

Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial

Yung‐Jue Bang, Hyun‐Tai Chung, Jun Xu et al. · Journal of Clinical Oncology · 2009 · 155 citations

Medicine, Molecular Medicine, Oncology +15

Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer

Christian Jackisch, Daniil Stroyakovskiy, Xavier Pivot et al. · JAMA Oncology · 2019 · 75 citations · Full text

Medicine, Oncology, Pharmacology +17

Quality of Life in the Trastuzumab for Gastric Cancer Trial

Taroh Satoh, Yung‐Jue Bang, Evgeny Gotovkin et al. · The Oncologist · 2014 · 57 citations · Full text

Medicine, Oncology, Pharmacology +14